A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris

A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris

Efficacy and Safety of Imsidolimab in Participants with Acne Vulgaris

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of imsidolimab in adolescent and adult participants with acne vulgaris (AV). This study also will characterize the pharmacokinetic (PK) profile of imsidolimab and explore the immune response to imsidolimab in participants with AV.

Key Inclusion Criteria:

• Diagnosis of moderate to severe facial AV
• Facial IGA) score of 3 (moderate) or 4 (severe)
• At least 20 and no more than 100 inflammatory lesions on the face
• No more than 100 non-inflammatory lesions on the face.
• No more than 5 nodules (≥5 millimeter [mm]) on the face

Key Exclusion Criteria:

• A participant with acne fulminans or conglobate or secondary acne will be excluded.